OBAGI MEDICAL acquired by BRIDGEPOINT

DHCare has entered into an agreement to acquire Ottobock's Human Mobility business, which specializes in manual and power wheelchairs, as well as pediatric mobility solutions. This transaction is part of Ottobock's strategy to refocus its resources on its core, high-growth businesses, including prosthetics, neuro-orthotics, and exoskeletons. The divested business generates approximately €80 million in annual revenue, employs around 270 staff members, and comprises the German Human Mobility companies, as well as veldink4Kids, a Dutch specialist in pediatric wheelchairs

CordenPharma, backed by private equity firm Astorg, entered into an agreement to acquire AmbioPharm, a US-based CDMO specializing in complex peptide APIs with manufacturing sites in the United States and China. The transaction is part of CordenPharma’s broader strategy to strengthen its position as a global leader in peptide therapeutics manufacturing, a high-growth segment driven by next-generation pharmaceutical innovation, including GLP-1 and other advanced peptide-based therapies. The acquisition adds complementary capabilities across solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), hybrid synthesis technologies, as well as downstream purification and lyophilization capacities

The closing of this oversubscribed 86.6 million dollar Series B financing represents a structural capitalization event designed to transition Ona Therapeutics into a clinical-stage oncology platform and fund operations through its primary clinical data readouts. This institutional funding round replaces early-stage venture capital with a deep-pocketed, clinically-focused investment syndicate capable of supporting the high cash-burn rate associated with executing Phase I/II clinical trials for lead program ONA-255 in breast cancer patients

The acquisition of a 51% controlling interest in Laboratoire Nutergia by 3i presents a primary leveraged buyout transaction designed to transition a mature, founder-led enterprise into an institutionalized platform capable of capturing pan-European market share. Following a competitive auction process managed by financial advisor Houlihan Lokey involving several leading private equity sponsors, 3i secured the transaction by leveraging its institutional heritage in consumer healthcare and demonstrating complete strategic alignment with the founding Lagarde family, who will retain a 49% minority stake and remain active corporate stewards

Motion Equity Partners has acquired a majority stake in Polaris, a leading manufacturer of omega-3 concentrates, from Demea Agro, which had invested in the company three years ago. This transaction is part of a broader strategy to drive external growth and international expansion, with ambitious plans to establish a US-based industrial site and double in size within the next five years. Historical shareholders of Polaris, including Cerea Partners, Seventure, and Picama, are reinvesting alongside Motion Equity Partners, which brings its expertise in supporting industrial companies in their international development

The transaction involves the all-cash acquisition of Apogee Therapeutics by AbbVie, as part of a strategic move to bolster AbbVie's immunology portfolio, particularly in the area of chronic inflammatory diseases with significant unmet medical needs. Apogee Therapeutics has developed a monoclonal antibody targeting interleukin-13, which has the potential to treat atopic dermatitis and other inflammatory conditions. The strategic rationale is also driven by the complementary nature of Apogee's assets with AbbVie's existing immunology portfolio, including its established treatments for inflammatory diseases

Stryker has completed the acquisition of Amplitude Vascular Systems, a private medical device company, which develops a next-generation intravascular lithotripsy (IVL) platform, designed to treat complex peripheral arterial disease, this acquisition represents a significant milestone in the expansion of Stryker's peripheral vascular portfolio, by integrating Amplitude Vascular Systems' innovative technology, which uses carbon dioxide-generated pressure waves, to optimize arterial diameter, while minimizing damage and improving deliverability, treatment speed, and therapeutic efficacy, with the goal of strengthening Stryker's position in peripheral vascular solutions, by offering solutions for physicians and patients, to treat cardiovascular disease, Stryker's strategy is to develop its portfolio of products and services, to improve patient and healthcare outcomes, by offering innovative and integrated solutions, for physicians, hospitals, and patients, financial and legal advisory services were provided by reputable consulting firms, to ensure the success of the operation

American Industrial Partners has finalized a definitive agreement to acquire Avanos Medical in an all-cash transaction, a maneuver designed to fundamentally reinforce the target's competitive positioning in the specialized medical technology arena. The strategic rationale for this transaction centers on an "operational-transformation" play, merging the target's industry-leading technical operational depth in nutrition and pain therapies with the acquirer's extensive history of implementing transformative operating agendas

In a structured minority growth equity transaction, specialized family capital investment firm For Talents has acquired a minority stake in Neftys Pharma. This strategic operation is executed alongside incumbent financial sponsors UI Investissement and GENEO Capital Entrepreneur, who are rolling over their investments after an initial four-year holding period. The transaction is fundamentally designed to facilitate the intergenerational transmission of the family-owned enterprise from founder Jacques Mignot to his son, Diego Mignot, who officially assumes the presidency

The acquisition of Céfiméca by Oury Medical represents a strategic consolidation within the French orthopedic and spinal medical device market. This transaction is the fifth build-up operation completed by Oury Medical in three years, following a platform strategy initiated by its lead investors. The primary rationale behind the deal is the creation of a comprehensive "One-Stop-Shop" offering for global orthopedic clients, combining Céfiméca’s specialized expertise in precision implants with Oury Medical’s established strength in surgical instrumentation